AIM Rule 26
The information contained within the section of this website is for the purposes of AIM Rule 26:
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Our mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Our ambition is to become the most influential life science company for researchers worldwide.
The company was founded in 1998 and has been listed on the AIM market of the London Stock Exchange since 2005.
To find out more.
Information on the Company Directors can be found here.
Information on Corporate Governance can be found here.
UK Takeover Code Applicability
The UK City Code on Takeovers and Mergers applies to the Company.
Country of Incorporation and Operations
Country of incorporation : England and Wales
Company registration number : 3509322
Main country of operation : United Kingdom
Annual Reports and Accounts
Annual Reports and Accounts for the last three years can be found here.
Details of Restrictions on the Transfer of Securities
There are no restrictions on the transfer of ordinary shares.
Details of any other Exchanges
The securities of the Company are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.
AIM securities in issue: As at 30 April 2019 there were 205,597,614 ordinary shares of 0.2 pence each.
As at 30 April 2019 the percentage of shares not held in public hands (as defined by AIM rule 26) was 23.05%.
The identity and shareholdings of the Company’s significant shareholders can be found here.
All Company Advisor Information can be found here.
This information was last updated on 31 October 2017.